Skip to content

Gemechu LAB

Mission Statement:

Identify actionable targets for the development of novel immunotherapies and cancer vaccines for developing safe and potent treatments for cancer.

Research Focus:

The Gemechu Laboratory focuses on developing novel therapeutics for cancer, including cancer vaccines and immune-modulating small molecules. Of particular interest is an immunomodulatory drug that has both anti-angiogenesis and anti-tumoral immune induction potential, which can be combined with immunotherapies for improving preclinical and clinical outcomes. Our lab is also interested in identifying the downstream target/s of immune‐mediated inflammatory processes for developing a safe and potent tumor microenvironment modifier.

VIC Projects List

Highlighted Publications

Humanized Cereblon Mice Revealed Two Distinct Therapeutic Pathways of Immunomodulatory Drugs.

Proc.Natl.Acad.Sci. U.S.A. (2018)115(46): 1180211807.
Gemechu Y, Millrine D, Hashimoto S, Prakash J, Sanchenkova K, Metwally H, Gyanu P, Kang S, and Kishimoto T.

Ligase Modulator, FPFT-2216, Offers a Protective Effect Against Myelodysplastic Syndrome.

J Immunol 2020;204 (1 Suppl) 163.7 Gemechu Y and Kishimoto T. A novel Cullin 4A/BCereblon E3

Rabex-5 is a Lenalidomide Target Molecule that Negatively Regulates TLR-Induced Type 1 IFN Production.

Proc.Natl.Acad.Sci. U.S.A. (2016)113(38):10625-30. Millrine D, Tei M, Gemechu Y, Kishimoto T.

Immunomodulatory Drugs Inhibit TLR4 Induced Type-1 Interferon Production Independently of Cereblon Via Suppression of the TRIF/IRF3 Pathway.

Int Immunol. (2016) 28(6):307-15. Millrine D, Miyata H, Tei M, Dubey P, Nyati K, Nakahama T, Gemechu Y, Ripley B, Kishimoto T.

The Novel Long Noncoding RNA AU021063, Induced by IL-6/Arid5a Signaling, Exacerbates Breast Cancer Invasion and Metastasis by Stabilizing Trib3 and Activating the Mek/Erk Pathway.

Cancer Letters (2021) 520: 295-306. Nyati K, Hashimoto S, Singh SK, Tekguc M, Metwally H, Liu Y, Okuzaki D, Gemechu Y, Sujin Kang, Kishimoto T.

Feedback Regulation of Arid5a and Ppar-γ2 Maintains Adipose Tissue Homeostasis.

Proc.Natl.Acad.Sci. U.S.A. (2019) 116(30):15128-33. Chalise J.P., Hashimoto SH, Parajuli G, Kang S, Singh Sh, Gemechu Y, Metwally H, Nyati K.K., Dubey P.K., Zaman M.M., Nagahama Y, H Hamza, Masuda K, and Kishimoto T.

A Noncanonical STAT1 Phosphorylation Expands its Transcriptional Activity into Regulating LPS Induced IL-6 and IL-12p40 Expression.

Sci. Signal. (2020)13:624, eaay0574.Metwally H, Tanaka T, Li S, Parajuli G, Kang S, Hanieh H, Hashimoto Sh , Chalise JP, Gemechu Y, Standley DM, and Kishimoto T.

Research Team

Sonia Mukherjee, MS

Research Technologist



Tayhlor Tanner, PhD candidate, Morehouse School of Medicine, Atlanta, Georgia

James Adeosun, MD candidate, University of Cambridge School of Clinical Medicine, United Kingdom Summer Research Intern

Abigail Colley, PhD Candidate, Department of Pathology, University of Cambridge United Kingdom, Summer Research Intern


Help us to advance now the medicines of the future.